# Biotech IP valuation Consultancies and data platforms that value biotechnology and pharmaceutical patent portfolios for licensing negotiations, M&A, litigation and capital raises — translating a patent estate covering therapeutics, diagnostics or platform technologies into a defensible monetary figure. Source: https://en.bioecon.ru/technology/biotech-ip-valuation/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: Intellectual-property valuation & licensing-benchmark services | OECD: Bioeconomy policy & governance | Regulator: none — private valuation practice, not a licensed regulatory function] Biotech IP valuation is a B2B services category in which specialist consultancies and data platforms assign a defensible monetary value to a biotechnology or pharmaceutical company's patent portfolio, supporting licensing negotiations, M&A due diligence, litigation damages and capital raises. Ocean Tomo runs engagement-based valuations for biotechnology startups, including a documented capital-raise engagement for a company holding IP covering cancer and rare-disease therapeutics and diagnostics. Consor IP Consulting applies AI-assisted methods to patent valuation, treating patents as strategic business assets rather than purely legal instruments. Charles River Associates (CRA) brings economic-valuation expertise to life-sciences disputes, including cases where the product being valued may never reach market — a distinctly biotech valuation problem. EverEdge Global, headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios. GreyB provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — built for IP counsel and licensing teams assessing monetization readiness, including standard-essential-patent (SEP) readiness reporting. Inngot, a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets for smaller biotech and life-sciences companies. The key directions of biotech IP valuation are: 1. **Engagement-based patent-portfolio valuation:** custom valuations for a specific transaction — licensing negotiation, M&A, or a capital raise — grounded in the patent estate's claims, remaining life and competitive position. 2. **AI-assisted valuation methodology:** applying machine-learning and data-driven models to patent valuation, moving beyond purely qualitative expert judgment. 3. **Litigation and damages valuation:** economic analysis supporting patent-infringement and licensing disputes, including cases involving products that have not yet reached market approval. 4. **Portfolio analytics and monetization readiness:** structured analysis of prosecution history, litigation exposure, claims and citations to assess which patents in a portfolio are genuinely ready for licensing or sale. ### Sectoral value chain ``` [Patent portfolio identification] ──> [Prior-art & claims analysis] ──> [Valuation methodology selection] │ (Royalty-rate benchmarking) │ [Negotiation/litigation support] <──── [Valuation report delivery] <─── [Monetary value determination] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Portfolio identification** | Cataloguing the patents, applications and other intangible assets that make up the biotech company's IP estate. | **In:** Patent filings, R&D records.
**Out:** IP asset inventory. | | **Prior-art and claims analysis** | Assessing patent strength, remaining life, prosecution history and litigation exposure for each asset. | **In:** IP asset inventory, prosecution files.
**Out:** Patent-strength assessment. | | **Valuation methodology selection** | Choosing an income-, market- or cost-based valuation approach suited to the asset class and the transaction context. | **In:** Patent-strength assessment.
**Out:** Selected valuation methodology. | | **Royalty-rate benchmarking** | Comparing the asset against comparable licensing deals and royalty-rate data to ground the valuation in market evidence. | **In:** Selected valuation methodology, deal-comparable data.
**Out:** Benchmarked royalty range. | | **Monetary value determination** | Producing a defensible monetary valuation figure or range for the patent or portfolio. | **In:** Benchmarked royalty range.
**Out:** Valuation figure/range. | | **Valuation report delivery** | Delivering the finished valuation report to support the client's licensing negotiation, M&A process or litigation. | **In:** Valuation figure/range.
**Out:** Delivered valuation report. | Cross-cutting technologies of the sector: - **Patent-valuation methodologies:** income-, market- and cost-based approaches adapted to the specific characteristics of a biotech or pharmaceutical patent estate. - **Royalty-rate benchmarking databases:** structured datasets of comparable licensing deals used to ground a valuation in observed market royalty rates. - **IP-portfolio analytics:** software analyzing prosecution history, litigation exposure, claims and citations to assess a patent portfolio's monetization readiness. --- ## US The United States hosts the largest concentration of biotech IP-valuation consultancies and royalty-rate data providers, several built on decades of patent-litigation and licensing-deal history. ### Ocean Tomo's engagement-based startup valuations, Consor's AI-assisted methodology, CRA's life-sciences litigation valuation - **Ocean Tomo:** runs engagement-based IP valuations for biotechnology startups, including capital-raise support for companies holding therapeutic and diagnostic patent portfolios. - **Consor IP Consulting:** applies AI-assisted methods to patent valuation, treating patents as strategic business assets in a data-driven valuation practice. - **Charles River Associates (CRA):** brings economic-valuation expertise to life-sciences disputes, including the distinctly biotech problem of valuing a product that may never reach market approval. --- ## CN China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese biotech IP-valuation firms searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Chinese biotech companies pursuing cross-border licensing or M&A typically engage the global valuation firms listed here, or domestic state-linked asset-appraisal institutions whose specific biotech-IP practices could not be confirmed in this screen. ### Cross-border biotech IP valuation served by global consultancies - **Cross-border engagement pattern:** Chinese biotech companies pursuing licensing deals or M&A with Western partners typically retain the global valuation firms listed in this article rather than a distinct domestic biotech-IP specialist. - **Domestic gap:** no Chinese-headquartered biotech IP-valuation firm confirmed by a live 2026 source was found during this screen. --- ## EU Europe and adjacent jurisdictions host specialist IP-valuation and intangible-asset consultancies serving smaller biotech and life-sciences clients alongside larger transactions. ### EverEdge's ten-asset-class valuation models, GreyB's portfolio analytics, Inngot's intangible-asset toolkit - **EverEdge Global:** headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios. - **GreyB:** provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — including standard-essential-patent readiness reporting for licensing teams. - **Inngot:** a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets, sized for smaller biotech and life-sciences companies. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Ocean Tomo** | 🇺🇸 USA | Engagement-based IP valuation | Biotech startup capital-raise support | commercial | | **Consor IP Consulting** | 🇺🇸 USA | AI-assisted patent valuation | Data-driven valuation methodology | commercial | | **Charles River Associates IP** | 🇺🇸 USA | Economic/IP litigation valuation | Life-sciences disputes practice | commercial | | **EverEdge Global** | 🇳🇿 New Zealand | Ten-asset-class valuation models | Pharma/biotech IP asset coverage | commercial | | **GreyB** | 🇮🇳 India | *IP Compass* portfolio analytics | SEP readiness, litigation exposure analysis | commercial | | **Inngot** | 🇬🇧 United Kingdom | Intangible-asset valuation toolkit | Sized for smaller biotech clients | commercial | --- ## Tech stack and innovations The biotech IP-valuation technology stack combines established valuation methodology with AI-assisted analytics and structured royalty-benchmarking data: 1. **Patent-valuation methodologies:** - Firms such as Ocean Tomo and Charles River Associates apply income-, market- and cost-based approaches adapted to biotech-specific circumstances, including products that have not yet reached regulatory approval. 2. **AI-assisted valuation and portfolio analytics:** - Consor IP Consulting applies AI-assisted methods to patent valuation; GreyB's IP Compass reviews prosecution history, litigation, claims and citations to assess monetization readiness. 3. **Royalty-rate benchmarking:** - ktMINE maintains royalty-rate range data drawn from thousands of biopharma licensing deals, grounding valuations in observed market transactions. --- ## Value chains and production pipelines ### Industrial pipeline for a biotech patent-portfolio valuation engagement ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Patent portfolio │ ───> │ 2. Prior-art & claims │ │ identification │ │ analysis │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Royalty-rate │ <─── │ 3. Valuation methodology │ │ benchmarking │ │ selection │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Monetary value │ ───> │ 6. Valuation report │ │ determination │ │ delivery │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Patent portfolio identification The valuation firm catalogues the patents, applications and other intangible assets that make up the biotech company's IP estate. #### Stage 2: Prior-art and claims analysis Analysts assess patent strength, remaining life, prosecution history and litigation exposure for each asset in the portfolio. #### Stage 3: Valuation methodology selection An income-, market- or cost-based valuation approach is selected to fit the specific asset class and the transaction context (licensing, M&A, litigation, capital raise). #### Stage 4: Royalty-rate benchmarking The asset is compared against comparable licensing deals and royalty-rate data to ground the valuation in observed market evidence rather than pure theory. #### Stage 5: Monetary value determination The methodology and benchmark data are combined to produce a defensible monetary valuation figure or range for the patent or portfolio. #### Stage 6: Valuation report delivery The finished valuation report is delivered to support the client's licensing negotiation, M&A process, capital raise or litigation.